{"entity": "publication", "iuid": "f592dcda0e684595bc8de93d13589074", "timestamp": "2026-08-23T10:12:59.600Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/f592dcda0e684595bc8de93d13589074.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/f592dcda0e684595bc8de93d13589074"}}, "title": "Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study.", "authors": [{"family": "Schiza", "given": "Aglaia", "initials": "A", "orcid": "0000-0002-5514-3637", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4a4589967d87426ba8587ddab8cbe8fb.json"}}, {"family": "Mauri", "given": "Davide", "initials": "D"}, {"family": "Fredriksson", "given": "Irma", "initials": "I"}, {"family": "Valachis", "given": "Antonios", "initials": "A"}], "type": "journal article", "published": "2021-04-00", "journal": {"title": "Breast Cancer Res. Treat.", "issn": "1573-7217", "volume": "186", "issue": "3", "pages": "779-789", "issn-l": "0167-6806"}, "abstract": "There are conflicting results on the potential role of HER2-status on the efficacy of aromatase inhibitors (AIs) and tamoxifen (TAM) in patients with hormone receptor (HR)-positive breast cancer (BC). The purpose of this population-based cohort study was to investigate the potential benefit of AIs compared to TAM as adjuvant therapy in postmenopausal BC patients by HER2-status in the era of modern therapy with HER2-blockade.\n\nA population-based cohort study was performed including all postmenopausal women diagnosed with HR-positive BC without distant metastasis between 2007 and 2012 in three healthcare regions in Sweden. We analyzed the breast cancer-specific survival (BCSS) and overall survival (OS) in two distinct cohorts (HER2-negative, HER2-positive) based on the type of endocrine therapy (ET) used. A propensity score matching was performed separately in the HER2-negative and HER2-positive cohorts, respectively.\n\nAfter propensity score matching, 4368 patients with HER2-negative and 214 patients with HER2-positive BC were available for analysis. In the HER2-negative cohort, an improved BCSS [Hazard Ratio (HR): 0.51; 95% confidence interval (CI): 0.34-0.77, p value < 0.001] and a trend toward improved OS (HR: 0.66; 95% CI: 0.41-1.08, p value = 0.093) in favor of AI-based therapy was observed. In the HER2-positive cohort, no statistically significant difference between AI-based ET and TAM was found in terms of either BCSS or OS, although the direction of HR was similar as in the HER2-negative cohort (HR for BCSS: 0.84; 95% CI: 0.14-5.04, p = 0.849; HR for OS: 0.62; 95% CI: 0.10-3.38, p = 0.345).\n\nOur study results, based on propensity-matched cohorts, did not support any predictive value of HER2-status on endocrine therapy in postmenopausal BC patients. AI-based ET remains the treatment of choice for postmenopausal BC patients with HR-positive disease in the modern era of HER2-directed therapy irrespective of HER2-status.", "doi": "10.1007/s10549-020-06022-5", "pmid": "33258078", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC8019428"}, {"db": "pii", "key": "10.1007/s10549-020-06022-5"}], "notes": [], "created": "2026-08-21T11:07:37.501Z", "modified": "2026-08-21T11:07:37.568Z"}